Adsorption enhanced biological treatment of hydrothermal liquefaction aqueous phase derived from municipal sludge.

Autor: Aktas K; UBC Bioreactor Technology Group, School of Engineering, The University of British Columbia, Okanagan Campus, Kelowna, British Columbia, Canada., Liu H; UBC Bioreactor Technology Group, School of Engineering, The University of British Columbia, Okanagan Campus, Kelowna, British Columbia, Canada., Basar IA; UBC Bioreactor Technology Group, School of Engineering, The University of British Columbia, Okanagan Campus, Kelowna, British Columbia, Canada., Eskicioglu C; UBC Bioreactor Technology Group, School of Engineering, The University of British Columbia, Okanagan Campus, Kelowna, British Columbia, Canada. Electronic address: cigdem.eskicioglu@ubc.ca.
Jazyk: angličtina
Zdroj: Bioresource technology [Bioresour Technol] 2024 Sep; Vol. 407, pp. 131093. Date of Electronic Publication: 2024 Jul 08.
DOI: 10.1016/j.biortech.2024.131093
Abstrakt: Hydrothermal liquefaction (HTL) is a promising method for municipal sludge valorization through waste minimization and biofuel production. The process wastewater, HTL aqueous, presents a significant challenge for scale-up due to recalcitrant compounds. In this study, granular activated carbon (GAC) was used to remove potential inhibitors from HTL aqueous through adsorption to enhance aerobic and anaerobic biological treatment. GAC removed up to 61 % chemical oxygen demand (COD), 50 % biochemical oxygen demand (BOD) and potential inhibitors, such as total phenolic compounds (87 %) and N-heterocycles (90 % of pyridines) at 100 g/L. Conversely, most volatile fatty acids remained in HTL aqueous. Subsequently, mesophilic and thermophilic specific methane potential increased by up to 97 % and 83 %, respectively. BOD increased by up to 50 %, which enhanced BOD/COD ratio from 81 % to 93 % before and after adsorption. This study established the groundwork for HTL aqueous adsorption, described mechanism for pollutant removal, and provided insights for biological treatment.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: